The Committee For Medicinal Products For Human Use Of The European Medicines Agency Adopted A Positive Opinion For Pfizer's Fidanacogene Elaparvovec, A One-time Gene Therapy For Severe Hemophilia B In Adult Patients
The Committee For Medicinal Products For Human Use Of The European Medicines Agency Adopted A Positive Opinion For Pfizer's Fidanacogene Elaparvovec, A One-time Gene Therapy For Severe Hemophilia B In Adult Patients
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.